Live news related to TRANSGENE stock (FR0005175080): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on TRANSGENE mainly cover M&A activity, analyst notes et share price moves. The stock trades at €0,73 on Euronext Paris, up 0,28% at the last update. This page lists the articles published on TRANSGENE stock to track the share price, company announcements and any item likely to influence market perception.
The Strasbourg-based biotech company indicated, in a press release published on October 5, 2026, that it will exhibit preclinical data on a chimeric o…
Strasbourg-based biotech company Transgene announced on October 1, 2026 that its management team will meet with institutional investors at an event or…
Strasbourg-based biotech Transgene published its accounts for the half-year ended June 30, 2026 on September 24, 2026, marked by a reduction in net lo…
Transgene has expanded the scope of its existing collaboration with ProBioGen. The Strasbourg-based group has concluded an additional license agreemen…
Transgene and NEC have published three-year follow-up data from phase 1 of a trial evaluating TG4050, the first individualized neoantigen therapeutic …
On Thursday in Strasbourg, Transgene presented encouraging preclinical results for TG-MVA, its next-generation vaccine candidate against monkeypox and…
Biotech company Transgene announced on Monday the initiation of a Phase 1 clinical trial for TG4070, its second candidate derived from the Myvac platf…
On Tuesday, Transgene announced the preclinical results of TG-MVA, a prophylactic vaccine candidate against monkeypox (mpox), leveraging its historica…
Transgene announces the completion of patient randomization in the Phase 2 segment of its clinical trial evaluating TG4050, a personalized therapeutic…
Transgene and NEC Bio B.V., a subsidiary of NEC Corporation, have entered into a licensing agreement on April 2, 2026, to continue the clinical develo…
